Rhumbline Advisers Decreases Position in DaVita Inc. (NYSE:DVA)

Rhumbline Advisers reduced its stake in DaVita Inc. (NYSE:DVA) by 12.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 134,125 shares of the company’s stock after selling 18,549 shares during the quarter. Rhumbline Advisers owned about 0.16% of DaVita worth $20,058,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in DVA. Transcendent Capital Group LLC purchased a new stake in shares of DaVita in the third quarter valued at $25,000. Blue Trust Inc. lifted its position in shares of DaVita by 56.4% in the third quarter. Blue Trust Inc. now owns 330 shares of the company’s stock valued at $54,000 after acquiring an additional 119 shares in the last quarter. Quarry LP purchased a new stake in shares of DaVita in the third quarter valued at $60,000. Versant Capital Management Inc lifted its position in shares of DaVita by 58.7% in the fourth quarter. Versant Capital Management Inc now owns 457 shares of the company’s stock valued at $68,000 after acquiring an additional 169 shares in the last quarter. Finally, Wingate Wealth Advisors Inc. purchased a new stake in shares of DaVita in the fourth quarter valued at $82,000. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Barclays upped their price objective on DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $162.80.

DaVita Stock Performance

NYSE DVA opened at $145.99 on Friday. The business’s 50-day moving average price is $161.24 and its 200 day moving average price is $157.81. DaVita Inc. has a twelve month low of $119.42 and a twelve month high of $179.60. The company has a market capitalization of $11.68 billion, a PE ratio of 13.59, a price-to-earnings-growth ratio of 1.01 and a beta of 0.94. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Thursday, February 13th. The company reported $2.24 EPS for the quarter, topping the consensus estimate of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. On average, research analysts predict that DaVita Inc. will post 10.72 earnings per share for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.